These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. Calvet CM; Vieira DF; Choi JY; Kellar D; Cameron MD; Siqueira-Neto JL; Gut J; Johnston JB; Lin L; Khan S; McKerrow JH; Roush WR; Podust LM J Med Chem; 2014 Aug; 57(16):6989-7005. PubMed ID: 25101801 [TBL] [Abstract][Full Text] [Related]
12. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218 [TBL] [Abstract][Full Text] [Related]
13. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946 [TBL] [Abstract][Full Text] [Related]
14. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection. Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643 [TBL] [Abstract][Full Text] [Related]
15. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. De Rycker M; Thomas J; Riley J; Brough SJ; Miles TJ; Gray DW PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004584. PubMed ID: 27082760 [TBL] [Abstract][Full Text] [Related]
16. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery. Ekins S; de Siqueira-Neto JL; McCall LI; Sarker M; Yadav M; Ponder EL; Kallel EA; Kellar D; Chen S; Arkin M; Bunin BA; McKerrow JH; Talcott C PLoS Negl Trop Dis; 2015; 9(6):e0003878. PubMed ID: 26114876 [TBL] [Abstract][Full Text] [Related]
17. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331 [TBL] [Abstract][Full Text] [Related]
18. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi. Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605 [TBL] [Abstract][Full Text] [Related]